Formula Shown to Support Eye Health in Human Clinical Study

89

Irvine, CA—BGG World has announced the results of a human clinical study on a formula for eye health that contains 200mg MyrtiPro bilberry extract, 6mg Astazine astaxanthin, and 10mg lutein.

Each piece of the formula has been previously shown to support eye health, according to the study:

  • Bilberry: Contains anthocyanins that have been shown to possess antioxidant properties, including cyanidin-3-glucoside, which promotes the regeneration of rhodopsin after conformational change on light absorption. Anthocyanins have been reported to help relieve eye fatigue, help the eyes focus on objects, improve contrast sensitivity, and improve tear fluid quality.
  • Astaxanthin: Reduces the degradation of nitric oxide, and has shown blood flow improving effects in a clinical trial. It has been shown to significantly increase retinal capillary blood flow near the optic disc, and is therefore expected to lead to reduced eye fatigue.
  • Lutein: Distributed in the retina, it acts as an antioxidant and absorbs blue light. It is also reported to improve visual acuity and contrast sensitivity.

The randomized, double-blind, placebo-controlled study was done on 44 healthy subjects experiencing eye fatigue during visual display terminal operations. Half the group was given the eye support formula, and half was given an identical placebo for six weeks.

Related: Tocotrienol, Astaxanthin Combo Shows Promise in Cognitive Health Study
Study Finds Eye Health Benefits for Sabinsa’s Macumax
Aker BioMarine Focuses on Brain and Eye Health Innovation

The results showed that the test group went from having significantly lower visual acuity than the placebo group at baseline, to having significantly higher visual acuity than the placebo group at the end of the 6 week test period. Test subjects felt that they had an easier time focusing, as well as an easier time seeing nearby objects and reading fine print.

BGG’s Global Chief Scientific Officer, Yanmei Li, Ph.D., commented in the press release: “Work at visual display terminals is a very common cause of visual fatigue. It is estimated that over 60% of visual display terminal users experience eye symptoms while more than 20% experience other issues like musculoskeletal problems. Given the millions of people using visual display terminals these conditions affect a substantial percentage of the population. We are very excited about the eye health benefits by this synergistic formula that is adding clinical evidence to support such a common discomfort.”